oral glp 1 agonist Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies FDA Approves Oral Semaglutide as

By establishing a safe in vitro concentration range and a safe intravenous dose, alongside elucidating the precise molecular mechanisms underlying its toxicity, this research provides a critical framework for evaluating the risk-benefit balance of CGA

Eur Food Res Technol 245:11691182 Ethics declarations Conflict of interest The authors declare that there is no conflict of interest

PMID 20599753

A recent study introduces a peptide PROTAC specifically designed to target and degrade the cysteine-histidine-rich 1 (CH1) domain of p300, a vital co-activator involved in oncogenic signaling pathways, particularly in PCa (Zhang et al., 2024)

elegans as a genetic model